Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CAPS Stock Alerts

Capstone Therapeutics (CAPS) Competitors

Capstone Therapeutics logo
$0.22 0.00 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.21 -0.01 (-2.29%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CAPS vs. MWYN, SOS, JBDI, CLWT, and INEO

Should you buy Capstone Therapeutics stock or one of its competitors? Capstone Therapeutics's main competitors and comparable companies include Marwynn (MWYN), SOS (SOS), JBDI (JBDI), Euro Tech (CLWT), and INNEOVA (INEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Capstone Therapeutics compare to Marwynn?

Capstone Therapeutics (NASDAQ:CAPS) and Marwynn (NASDAQ:MWYN) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marwynn
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 29.8% of Marwynn shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Capstone Therapeutics has a beta of -1.52, meaning that its share price is 252% less volatile than the broader market. Comparatively, Marwynn has a beta of 3.57, meaning that its share price is 257% more volatile than the broader market.

Marwynn has lower revenue, but higher earnings than Capstone Therapeutics. Marwynn is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.07-$21.23M-$3.35N/A
Marwynn$4.24M4.95-$3.92M-$0.22N/A

Capstone Therapeutics has a net margin of -36.51% compared to Marwynn's net margin of -59.88%. Marwynn's return on equity of -134.21% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-36.51% -144.43% -40.48%
Marwynn -59.88%-134.21%-45.24%

In the previous week, Capstone Therapeutics had 2 more articles in the media than Marwynn. MarketBeat recorded 4 mentions for Capstone Therapeutics and 2 mentions for Marwynn. Marwynn's average media sentiment score of 1.44 beat Capstone Therapeutics' score of -0.28 indicating that Marwynn is being referred to more favorably in the news media.

Company Overall Sentiment
Capstone Therapeutics Neutral
Marwynn Positive

Summary

Capstone Therapeutics beats Marwynn on 7 of the 13 factors compared between the two stocks.

How does Capstone Therapeutics compare to SOS?

SOS (NYSE:SOS) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOS
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

SOS has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the broader market.

SOS has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. SOS's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SOSN/A N/A N/A
Capstone Therapeutics -36.51%-144.43%-40.48%

1.9% of SOS shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 2.7% of SOS shares are held by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Capstone Therapeutics had 4 more articles in the media than SOS. MarketBeat recorded 4 mentions for Capstone Therapeutics and 0 mentions for SOS. SOS's average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.28 indicating that SOS is being referred to more favorably in the media.

Company Overall Sentiment
SOS Neutral
Capstone Therapeutics Neutral

Capstone Therapeutics has lower revenue, but higher earnings than SOS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOS$154.29M0.09-$97.32MN/AN/A
Capstone Therapeutics$48.11M0.07-$21.23M-$3.35N/A

Summary

SOS beats Capstone Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to JBDI?

Capstone Therapeutics (NASDAQ:CAPS) and JBDI (NASDAQ:JBDI) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Capstone Therapeutics has a beta of -1.52, indicating that its share price is 252% less volatile than the broader market. Comparatively, JBDI has a beta of -1.12, indicating that its share price is 212% less volatile than the broader market.

JBDI has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. JBDI's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-36.51% -144.43% -40.48%
JBDI N/A N/A N/A

In the previous week, Capstone Therapeutics had 2 more articles in the media than JBDI. MarketBeat recorded 4 mentions for Capstone Therapeutics and 2 mentions for JBDI. JBDI's average media sentiment score of 0.44 beat Capstone Therapeutics' score of -0.28 indicating that JBDI is being referred to more favorably in the news media.

Company Overall Sentiment
Capstone Therapeutics Neutral
JBDI Neutral

JBDI has lower revenue, but higher earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.07-$21.23M-$3.35N/A
JBDI$8.44M1.57-$2.72MN/AN/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
JBDI
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

JBDI beats Capstone Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to Euro Tech?

Capstone Therapeutics (NASDAQ:CAPS) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the broader market. Comparatively, Euro Tech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Euro Tech shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Comparatively, 79.0% of Euro Tech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Euro Tech has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Euro Tech's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-36.51% -144.43% -40.48%
Euro Tech N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Euro Tech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Capstone Therapeutics had 2 more articles in the media than Euro Tech. MarketBeat recorded 4 mentions for Capstone Therapeutics and 2 mentions for Euro Tech. Euro Tech's average media sentiment score of 1.43 beat Capstone Therapeutics' score of -0.28 indicating that Euro Tech is being referred to more favorably in the news media.

Company Overall Sentiment
Capstone Therapeutics Neutral
Euro Tech Positive

Euro Tech has lower revenue, but higher earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.07-$21.23M-$3.35N/A
Euro Tech$13.27M0.95$160KN/AN/A

Summary

Euro Tech beats Capstone Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to INNEOVA?

INNEOVA (NASDAQ:INEO) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

INNEOVA has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. INNEOVA's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
INNEOVAN/A N/A N/A
Capstone Therapeutics -36.51%-144.43%-40.48%

In the previous week, Capstone Therapeutics had 2 more articles in the media than INNEOVA. MarketBeat recorded 4 mentions for Capstone Therapeutics and 2 mentions for INNEOVA. INNEOVA's average media sentiment score of 1.43 beat Capstone Therapeutics' score of -0.28 indicating that INNEOVA is being referred to more favorably in the media.

Company Overall Sentiment
INNEOVA Positive
Capstone Therapeutics Neutral

INNEOVA has higher revenue and earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INNEOVA$58.42M0.17-$400KN/AN/A
Capstone Therapeutics$48.11M0.07-$21.23M-$3.35N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INNEOVA
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

INNEOVA has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, meaning that its share price is 252% less volatile than the broader market.

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

INNEOVA beats Capstone Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPS vs. The Competition

Export
MetricCapstone TherapeuticsTrading Companies & Distributors IndustryIndustrials SectorNASDAQ Exchange
Market Cap$3.32M$9.43B$10.92B$13.10B
Dividend YieldN/A3.39%97.21%10.45%
P/E Ratio-0.0729.2027.7925.28
Price / Sales0.0723.51339.1187.71
Price / CashN/A48.8124.9550.90
Price / Book0.273.764.786.24
Net Income-$21.23M$370.07M$609.43M$347.60M
7 Day Performance-22.70%1.35%0.79%1.07%
1 Month Performance-15.11%3.93%3.21%1.03%
1 Year Performance-83.10%9.76%14.27%20.77%

Capstone Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPS
Capstone Therapeutics
0.3664 of 5 stars		$0.22
-0.3%		N/A-82.5%$3.32M$48.11MN/A38
MWYN
Marwynn
0.9481 of 5 stars		$0.67
-11.1%		N/A-6.7%$15.25M$4.24MN/A27
SOS
SOS
0.2976 of 5 stars		$0.85
-7.0%		N/A-55.0%$14.81M$154.29MN/A170
JBDI
JBDI
0.463 of 5 stars		$1.39
+7.8%		N/A-33.0%$12.27M$8.44MN/A121
CLWT
Euro Tech
1.1083 of 5 stars		$1.49
flat		N/A+37.8%$11.10M$13.27MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Gold buyout deals have handed shareholders overnight gains up to 79 percent
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel